title: [Aclidinium bromide improves the lung function and reduces dyspnoea in patients with COPD].
abstract: Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.
authors.affiliation: Lungemedicinsk Afdeling 253, Hvidovre Hospital, Kettegård Alle 30, 2650 Hvidovre. csulrik@dadlnet.dk.
authors.forename: Charlotte Suppli
authors.initials: CS
authors.lastname: Ulrik
mesh_terms: D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D004417:Dyspnea / Q000188:drug therapy; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011788:Quality of Life; D011859:Radiography; D016896:Treatment Outcome; D014326:Tropanes / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D014326:Tropanes; C542859:aclidinium bromide